These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1071 related articles for article (PubMed ID: 24429703)

  • 21. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution.
    Kim H; Zheng S; Amini SS; Virk SM; Mikkelsen T; Brat DJ; Grimsby J; Sougnez C; Muller F; Hu J; Sloan AE; Cohen ML; Van Meir EG; Scarpace L; Laird PW; Weinstein JN; Lander ES; Gabriel S; Getz G; Meyerson M; Chin L; Barnholtz-Sloan JS; Verhaak RG
    Genome Res; 2015 Mar; 25(3):316-27. PubMed ID: 25650244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity.
    Kim TM; Jung SH; An CH; Lee SH; Baek IP; Kim MS; Park SW; Rhee JK; Lee SH; Chung YJ
    Clin Cancer Res; 2015 Oct; 21(19):4461-72. PubMed ID: 25979483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutational analysis and clinical correlation of metastatic colorectal cancer.
    Russo AL; Borger DR; Szymonifka J; Ryan DP; Wo JY; Blaszkowsky LS; Kwak EL; Allen JN; Wadlow RC; Zhu AX; Murphy JE; Faris JE; Dias-Santagata D; Haigis KM; Ellisen LW; Iafrate AJ; Hong TS
    Cancer; 2014 May; 120(10):1482-90. PubMed ID: 24500602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic complexity of multiple myeloma and its clinical implications.
    Manier S; Salem KZ; Park J; Landau DA; Getz G; Ghobrial IM
    Nat Rev Clin Oncol; 2017 Feb; 14(2):100-113. PubMed ID: 27531699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma.
    Walker BA; Wardell CP; Melchor L; Hulkki S; Potter NE; Johnson DC; Fenwick K; Kozarewa I; Gonzalez D; Lord CJ; Ashworth A; Davies FE; Morgan GJ
    Blood; 2012 Aug; 120(5):1077-86. PubMed ID: 22573403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation.
    Kalakonda N; Rothwell DG; Scarffe JH; Norton JD
    Blood; 2001 Sep; 98(5):1555-60. PubMed ID: 11520807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CloneCNA: detecting subclonal somatic copy number alterations in heterogeneous tumor samples from whole-exome sequencing data.
    Yu Z; Li A; Wang M
    BMC Bioinformatics; 2016 Aug; 17():310. PubMed ID: 27538789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.
    Tan DS; Camilleri-Broët S; Tan EH; Alifano M; Lim WT; Bobbio A; Zhang S; Ng QS; Ang MK; Iyer NG; Takano A; Lim KH; Régnard JF; Tan P; Broët P
    Int J Cancer; 2014 Sep; 135(5):1092-100. PubMed ID: 24482041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
    Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
    Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coaltered
    Datta J; Smith JJ; Chatila WK; McAuliffe JC; Kandoth C; Vakiani E; Frankel TL; Ganesh K; Wasserman I; Lipsyc-Sharf M; Guillem J; Nash GM; Paty PB; Weiser MR; Saltz LB; Berger MF; Jarnagin WR; Balachandran V; Kingham TP; Kemeny NE; Cercek A; Garcia-Aguilar J; Taylor BS; Viale A; Yaeger R; Solit DB; Schultz N; D'Angelica MI
    Clin Cancer Res; 2020 Mar; 26(5):1077-1085. PubMed ID: 31719050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activating
    Shirazi F; Jones RJ; Singh RK; Zou J; Kuiatse I; Berkova Z; Wang H; Lee HC; Hong S; Dick L; Chattopadhyay N; Orlowski RZ
    Proc Natl Acad Sci U S A; 2020 Aug; 117(33):20004-20014. PubMed ID: 32747568
    [No Abstract]   [Full Text] [Related]  

  • 32. The chronological sequence of somatic mutations in early gastric carcinogenesis inferred from multiregion sequencing of gastric adenomas.
    Lim CH; Cho YK; Kim SW; Choi MG; Rhee JK; Chung YJ; Lee SH; Kim TM
    Oncotarget; 2016 Jun; 7(26):39758-39767. PubMed ID: 27175599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of genetic subclonal evolution in pancreatic cancer mouse models.
    Niknafs N; Zhong Y; Moral JA; Zhang L; Shao MX; Lo A; Makohon-Moore A; Iacobuzio-Donahue CA; Karchin R
    Nat Commun; 2019 Nov; 10(1):5435. PubMed ID: 31780749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spectrum of EGFR gene copy number changes and KRAS gene mutation status in Korean triple negative breast cancer patients.
    Kim Y; Kim J; Lee HD; Jeong J; Lee W; Lee KA
    PLoS One; 2013; 8(10):e79014. PubMed ID: 24205362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted sequencing-based analyses of candidate gene variants in ulcerative colitis-associated colorectal neoplasia.
    Chakrabarty S; Varghese VK; Sahu P; Jayaram P; Shivakumar BM; Pai CG; Satyamoorthy K
    Br J Cancer; 2017 Jun; 117(1):136-143. PubMed ID: 28524162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas.
    Gala MK; Mizukami Y; Le LP; Moriichi K; Austin T; Yamamoto M; Lauwers GY; Bardeesy N; Chung DC
    Gastroenterology; 2014 Feb; 146(2):520-9. PubMed ID: 24512911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.
    Kortuem KM; Braggio E; Bruins L; Barrio S; Shi CS; Zhu YX; Tibes R; Viswanatha D; Votruba P; Ahmann G; Fonseca R; Jedlowski P; Schlam I; Kumar S; Bergsagel PL; Stewart AK
    Blood Cancer J; 2016 Feb; 6(2):e397. PubMed ID: 26918361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Targets and New Agents in High-Risk Multiple Myeloma.
    Nooka AK; Lonial S
    Am Soc Clin Oncol Educ Book; 2016; 35():e431-41. PubMed ID: 27249751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study.
    Shi J; Hua X; Zhu B; Ravichandran S; Wang M; Nguyen C; Brodie SA; Palleschi A; Alloisio M; Pariscenti G; Jones K; Zhou W; Bouk AJ; Boland J; Hicks B; Risch A; Bennett H; Luke BT; Song L; Duan J; Liu P; Kohno T; Chen Q; Meerzaman D; Marconett C; Laird-Offringa I; Mills I; Caporaso NE; Gail MH; Pesatori AC; Consonni D; Bertazzi PA; Chanock SJ; Landi MT
    PLoS Med; 2016 Dec; 13(12):e1002162. PubMed ID: 27923066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of intratumoral heterogeneity of oncogenic driver mutations in surgically-resected lung adenocarcinoma: implications of percutaneous biopsy-based molecular assay for target-directed therapy.
    Kim HK; Lee HY; Choi YL; Choi SJ; Choi H; Lee J; Han J; Ahn MJ; Lee KS; Kim J
    Anticancer Res; 2014 Feb; 34(2):707-14. PubMed ID: 24511003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.